◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY

Home › All stocks › S › SENS

Senseonics Holdings, Inc. Common Stock (SENS) Financial History

20 years of revenue, earnings, cash-flow and balance-sheet history from public filings.

HEALTHCARE · MEDICAL DEVICES · DATA UPDATED 2026-10-02

Senseonics Holdings, Inc. Common Stock (SENS) operates in the MEDICAL DEVICES industry and is headquartered in Germantown, United States with about 130 employees. Its market capitalization is roughly $503 million. In the fiscal year ended 2025-12-31, SENS reported $35M in revenue and ($69M) in net income.

Senseonics Holdings, Inc., a commercial-stage medical technology company, focuses on development and manufacturing of continuous glucose monitoring (CGM) systems for people with diabetes in the United States and internationally.

Interactive charts & full statements → Open the SENS valuation workbench →

SENS Revenue & Earnings History — Annual Income Statement

Income statement	TTM → 2026-06-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31
Total Revenue	$49M	$35M	$22M	$22M	$16M	$14M	$5M	$21M	$19M	$6M	$0M	$0M	$0M	$0M
Gross Profit	$27M	$16M	$1M	$3M	$3M	($1M)	($17M)	($19M)	($8M)	($3M)	$0M	$0M	$0M	$0M
Gross Margin %	54.9%	44.7%	2.4%	13.8%	16.6%	-5.9%	-350.9%	-91.3%	-43.1%	-53.1%	-98.8%	100.0%	—	70.6%
Operating Income (EBIT)	($108M)	($68M)	($75M)	($76M)	($69M)	($57M)	($79M)	($131M)	($88M)	($56M)	($42M)	($29M)	($19M)	($19M)
Operating Margin %	-223.2%	-193.8%	-333.0%	-337.7%	-418.7%	-418.1%	-1598.9%	-613.4%	-463.1%	-883.6%	-12781.0%	-75821.1%	—	-110523.5%
Net Income	($109M)	($69M)	($79M)	($60M)	$142M	($302M)	($175M)	($116M)	($94M)	($59M)	($44M)	($30M)	($19M)	($19M)
Net Margin %	-225.3%	-196.0%	-349.8%	-269.7%	867.2%	-2211.9%	-3539.5%	-542.5%	-496.9%	-927.4%	-13231.9%	-78623.7%	—	-110464.7%
EBITDA	($102M)	($63M)	($69M)	($48M)	$162M	($285M)	($158M)	($99M)	($85M)	($56M)	($42M)	($29M)	($19M)	($19M)
Earnings Per Share (EPS)	$-2.27	$-1.66	$-2.50	$-2.13	$4.60	$-14.32	$-15.37	$-12.24	$-11.94	$-10.19	$-9.84	$-6.53	$-4.12	$-4.93
Shares Outstanding (M)	58M	42M	31M	28M	31M	21M	11M	9M	8M	6M	4M	5M	5M	4M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

SENS Quarterly Revenue & Earnings — Last 8 Quarters

Quarterly income statement	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30
Total Revenue	$14M	$12M	$14M	$8M	$7M	$6M	$8M	$4M
Gross Profit	$9M	$7M	$8M	$3M	$3M	$2M	$4M	($4M)
Gross Margin %	59.1%	59.3%	53.8%	42.8%	46.9%	24.1%	47.6%	-95.0%
Operating Income (EBIT)	($36M)	($32M)	($21M)	($20M)	($14M)	($13M)	($14M)	($23M)
Operating Margin %	-248.5%	-271.9%	-146.8%	-242.1%	-215.4%	-215.6%	-172.0%	-535.9%
Net Income	($37M)	($32M)	($21M)	($20M)	($15M)	($14M)	($15M)	($24M)
Net Margin %	-253.4%	-276.1%	-146.1%	-241.3%	-218.1%	-227.9%	-186.5%	-562.4%
EBITDA	($35M)	($31M)	($19M)	($18M)	($13M)	($12M)	($13M)	($22M)
Earnings Per Share (EPS)	$-0.63	$-0.71	$-0.50	$-0.43	$-0.49	$-0.40	$-0.46	$-0.77
Shares Outstanding (M)	58M	46M	42M	45M	30M	36M	33M	31M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

SENS Free Cash Flow History

Cash flow	TTM → 2026-06-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31
Cash from Operations (CFO)	($96M)	($59M)	($60M)	($70M)	($66M)	($56M)	($67M)	($136M)	($91M)	($56M)	($38M)	($25M)	($19M)	($17M)
Capital Expenditures (CapEx)	$1M	$1M	$2M	$0M	$0M	$0M	$0M	$1M	$1M	$0M	$0M	$0M	$0M	$0M
Free Cash Flow (FCF)	($97M)	($60M)	($63M)	($71M)	($67M)	($56M)	($68M)	($137M)	($92M)	($56M)	($38M)	($26M)	($19M)	($17M)
FCF Margin %	-199.5%	-170.9%	-279.0%	-314.9%	-406.5%	-411.6%	-1366.0%	-643.6%	-485.2%	-880.0%	-11594.9%	-67544.7%	—	-101676.5%
Dividends Paid	—	—	—	—	$3M	$5M	$1M	—	—	—	—	—	—	—

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

SENS Quarterly Free Cash Flow — Last 8 Quarters

Quarterly cash flow	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30
Cash from Operations (CFO)	($30M)	($32M)	($18M)	($16M)	($9M)	($16M)	($14M)	($15M)
Capital Expenditures (CapEx)	$0M	$0M	$0M	$0M	$0M	$0M	$0M	$0M
Free Cash Flow (FCF)	($30M)	($32M)	($18M)	($16M)	($9M)	($17M)	($14M)	($15M)
FCF Margin %	-209.6%	-274.4%	-128.8%	-197.4%	-141.2%	-263.9%	-172.1%	-352.3%

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

SENS Balance Sheet History

Balance sheet	2026-06-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31
Total Assets	$177M	$126M	$100M	$138M	$178M	$199M	$36M	$133M	$160M	$46M	$22M	$5M	$20M	$0M
Cash & Cash Equivalents	$45M	$41M	$75M	$76M	$36M	$33M	$18M	$96M	$137M	$16M	$13M	$4M	$19M	$0M
Total Liabilities	$87M	$65M	$117M	$102M	$180M	$384M	$180M	$141M	$89M	$39M	$27M	$15M	$12M	$0M
Total Debt (Short + Long-Term)	$57M	$36M	$55M	$42M	$73M	$64M	$61M	$117M	$51M	$24M	$19M	$10M	$20M	$0M
Total Shareholders' Equity	$90M	$61M	($17M)	$36M	($3M)	($186M)	($144M)	($9M)	$71M	$7M	($5M)	($10M)	$8M	$6M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive SENS viewer.

Other Companies in MEDICAL DEVICES

BVS · Bioventus Inc — $748 million
TCMD · Tactile Systems Technology Inc — $561 million
AVR · Anteris Technologies Global Corp. Common Stock — $545 million
SGHT · Sight Sciences Inc — $513 million
DCTH · Delcath Systems Inc — $500 million
CERS · Cerus Corporation — $472 million
SSII · SS Innovations International Inc. Common Stock — $467 million
BWAY · Brainsway Ltd — $449 million

← SENORES All “S” companies SENSEXADD →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.